Hemostasis testing and therapeutic plasma exchange: Results of a practice survey

Nicole D Zantek, Monica B. Pagano, Marian A. Rollins-Raval, Roy E. Smith, Amy E. Schmidt, Jason E. Crane, Leonard I. Boral, Yanhua Li, Annika M. Svensson, Chisa Yamada, Yanyun Wu, Edward C.C. Wong

Research output: Contribution to journalArticle

Abstract

Introduction: Performing therapeutic plasma exchange (TPE) with albumin replacement decreases coagulation factor and platelet levels. No defined guidelines exist regarding laboratory testing to assess hemostasis in patients undergoing TPE. Materials and methods: A survey to evaluate hemostasis testing with TPE was distributed using online survey software. One response per institution was analyzed based on a hierarchical algorithm, excluding membrane filtration users, resulting in a maximum of 120 respondents per question. Descriptive analysis was performed with results reported as the number and/or frequency (%) of respondents to each question. Results: The practices represented vary by institution type, number of apheresis procedures per year, and performance of TPE on children. Prior to TPE planned with albumin replacement, many respondents obtain laboratory studies for almost all patients (54.9% outpatients and 68.7% inpatients); however, some do not routinely obtain laboratory studies (9.7% outpatients and 4.4% inpatients). Hemoglobin/hematocrit, platelet count, fibrinogen, partial thromboplastin time (aPTT), and international normalized ratio (INR) are obtained prior to all TPE by 62.5%, 53.4%, 31.0%, 18.1%, and 17.7% of respondents, respectively; however, 1.0%, 8.7%, 29.0%, 38.3%, and 35.4%, respectively, do not routinely obtain these studies. Variation was observed in laboratory threshold values for action; the most common reported were hemoglobin/hematocrit <7 g/dL or 21% (31.0%), platelet count <50 × 10 9 /L (24.1%), fibrinogen <100 mg/dL (65.3%), aPTT >reference range and >1.5 times reference range (tied, 28.1%), and INR >1.5 (20.7%). Conclusions: Practice variation exists in hemostasis laboratory testing and threshold values for action with TPE. Further studies are needed to determine optimal hemostasis testing strategies with TPE.

Original languageEnglish (US)
Pages (from-to)26-32
Number of pages7
JournalJournal of clinical apheresis
Volume34
Issue number1
DOIs
StatePublished - Feb 1 2019

Fingerprint

Plasma Exchange
Hemostasis
International Normalized Ratio
Therapeutics
Hematocrit
Inpatients
Albumins
Reference Values
Hemoglobins
Outpatients
Blood Component Removal
Blood Coagulation Factors
Partial Thromboplastin Time
Surveys and Questionnaires
Platelet Count
Fibrinogen
Blood Platelets
Software
Guidelines
Membranes

Keywords

  • coagulation
  • fibrinogen
  • international normalized ratio
  • partial thromboplastin time
  • plasmapheresis

PubMed: MeSH publication types

  • Journal Article

Cite this

Zantek, N. D., Pagano, M. B., Rollins-Raval, M. A., Smith, R. E., Schmidt, A. E., Crane, J. E., ... Wong, E. C. C. (2019). Hemostasis testing and therapeutic plasma exchange: Results of a practice survey. Journal of clinical apheresis, 34(1), 26-32. https://doi.org/10.1002/jca.21666

Hemostasis testing and therapeutic plasma exchange : Results of a practice survey. / Zantek, Nicole D; Pagano, Monica B.; Rollins-Raval, Marian A.; Smith, Roy E.; Schmidt, Amy E.; Crane, Jason E.; Boral, Leonard I.; Li, Yanhua; Svensson, Annika M.; Yamada, Chisa; Wu, Yanyun; Wong, Edward C.C.

In: Journal of clinical apheresis, Vol. 34, No. 1, 01.02.2019, p. 26-32.

Research output: Contribution to journalArticle

Zantek, ND, Pagano, MB, Rollins-Raval, MA, Smith, RE, Schmidt, AE, Crane, JE, Boral, LI, Li, Y, Svensson, AM, Yamada, C, Wu, Y & Wong, ECC 2019, 'Hemostasis testing and therapeutic plasma exchange: Results of a practice survey', Journal of clinical apheresis, vol. 34, no. 1, pp. 26-32. https://doi.org/10.1002/jca.21666
Zantek, Nicole D ; Pagano, Monica B. ; Rollins-Raval, Marian A. ; Smith, Roy E. ; Schmidt, Amy E. ; Crane, Jason E. ; Boral, Leonard I. ; Li, Yanhua ; Svensson, Annika M. ; Yamada, Chisa ; Wu, Yanyun ; Wong, Edward C.C. / Hemostasis testing and therapeutic plasma exchange : Results of a practice survey. In: Journal of clinical apheresis. 2019 ; Vol. 34, No. 1. pp. 26-32.
@article{3da31262467346eb9e9e380f8f0ea618,
title = "Hemostasis testing and therapeutic plasma exchange: Results of a practice survey",
abstract = "Introduction: Performing therapeutic plasma exchange (TPE) with albumin replacement decreases coagulation factor and platelet levels. No defined guidelines exist regarding laboratory testing to assess hemostasis in patients undergoing TPE. Materials and methods: A survey to evaluate hemostasis testing with TPE was distributed using online survey software. One response per institution was analyzed based on a hierarchical algorithm, excluding membrane filtration users, resulting in a maximum of 120 respondents per question. Descriptive analysis was performed with results reported as the number and/or frequency ({\%}) of respondents to each question. Results: The practices represented vary by institution type, number of apheresis procedures per year, and performance of TPE on children. Prior to TPE planned with albumin replacement, many respondents obtain laboratory studies for almost all patients (54.9{\%} outpatients and 68.7{\%} inpatients); however, some do not routinely obtain laboratory studies (9.7{\%} outpatients and 4.4{\%} inpatients). Hemoglobin/hematocrit, platelet count, fibrinogen, partial thromboplastin time (aPTT), and international normalized ratio (INR) are obtained prior to all TPE by 62.5{\%}, 53.4{\%}, 31.0{\%}, 18.1{\%}, and 17.7{\%} of respondents, respectively; however, 1.0{\%}, 8.7{\%}, 29.0{\%}, 38.3{\%}, and 35.4{\%}, respectively, do not routinely obtain these studies. Variation was observed in laboratory threshold values for action; the most common reported were hemoglobin/hematocrit <7 g/dL or 21{\%} (31.0{\%}), platelet count <50 × 10 9 /L (24.1{\%}), fibrinogen <100 mg/dL (65.3{\%}), aPTT >reference range and >1.5 times reference range (tied, 28.1{\%}), and INR >1.5 (20.7{\%}). Conclusions: Practice variation exists in hemostasis laboratory testing and threshold values for action with TPE. Further studies are needed to determine optimal hemostasis testing strategies with TPE.",
keywords = "coagulation, fibrinogen, international normalized ratio, partial thromboplastin time, plasmapheresis",
author = "Zantek, {Nicole D} and Pagano, {Monica B.} and Rollins-Raval, {Marian A.} and Smith, {Roy E.} and Schmidt, {Amy E.} and Crane, {Jason E.} and Boral, {Leonard I.} and Yanhua Li and Svensson, {Annika M.} and Chisa Yamada and Yanyun Wu and Wong, {Edward C.C.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1002/jca.21666",
language = "English (US)",
volume = "34",
pages = "26--32",
journal = "Journal of Clinical Apheresis",
issn = "0733-2459",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Hemostasis testing and therapeutic plasma exchange

T2 - Results of a practice survey

AU - Zantek, Nicole D

AU - Pagano, Monica B.

AU - Rollins-Raval, Marian A.

AU - Smith, Roy E.

AU - Schmidt, Amy E.

AU - Crane, Jason E.

AU - Boral, Leonard I.

AU - Li, Yanhua

AU - Svensson, Annika M.

AU - Yamada, Chisa

AU - Wu, Yanyun

AU - Wong, Edward C.C.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Introduction: Performing therapeutic plasma exchange (TPE) with albumin replacement decreases coagulation factor and platelet levels. No defined guidelines exist regarding laboratory testing to assess hemostasis in patients undergoing TPE. Materials and methods: A survey to evaluate hemostasis testing with TPE was distributed using online survey software. One response per institution was analyzed based on a hierarchical algorithm, excluding membrane filtration users, resulting in a maximum of 120 respondents per question. Descriptive analysis was performed with results reported as the number and/or frequency (%) of respondents to each question. Results: The practices represented vary by institution type, number of apheresis procedures per year, and performance of TPE on children. Prior to TPE planned with albumin replacement, many respondents obtain laboratory studies for almost all patients (54.9% outpatients and 68.7% inpatients); however, some do not routinely obtain laboratory studies (9.7% outpatients and 4.4% inpatients). Hemoglobin/hematocrit, platelet count, fibrinogen, partial thromboplastin time (aPTT), and international normalized ratio (INR) are obtained prior to all TPE by 62.5%, 53.4%, 31.0%, 18.1%, and 17.7% of respondents, respectively; however, 1.0%, 8.7%, 29.0%, 38.3%, and 35.4%, respectively, do not routinely obtain these studies. Variation was observed in laboratory threshold values for action; the most common reported were hemoglobin/hematocrit <7 g/dL or 21% (31.0%), platelet count <50 × 10 9 /L (24.1%), fibrinogen <100 mg/dL (65.3%), aPTT >reference range and >1.5 times reference range (tied, 28.1%), and INR >1.5 (20.7%). Conclusions: Practice variation exists in hemostasis laboratory testing and threshold values for action with TPE. Further studies are needed to determine optimal hemostasis testing strategies with TPE.

AB - Introduction: Performing therapeutic plasma exchange (TPE) with albumin replacement decreases coagulation factor and platelet levels. No defined guidelines exist regarding laboratory testing to assess hemostasis in patients undergoing TPE. Materials and methods: A survey to evaluate hemostasis testing with TPE was distributed using online survey software. One response per institution was analyzed based on a hierarchical algorithm, excluding membrane filtration users, resulting in a maximum of 120 respondents per question. Descriptive analysis was performed with results reported as the number and/or frequency (%) of respondents to each question. Results: The practices represented vary by institution type, number of apheresis procedures per year, and performance of TPE on children. Prior to TPE planned with albumin replacement, many respondents obtain laboratory studies for almost all patients (54.9% outpatients and 68.7% inpatients); however, some do not routinely obtain laboratory studies (9.7% outpatients and 4.4% inpatients). Hemoglobin/hematocrit, platelet count, fibrinogen, partial thromboplastin time (aPTT), and international normalized ratio (INR) are obtained prior to all TPE by 62.5%, 53.4%, 31.0%, 18.1%, and 17.7% of respondents, respectively; however, 1.0%, 8.7%, 29.0%, 38.3%, and 35.4%, respectively, do not routinely obtain these studies. Variation was observed in laboratory threshold values for action; the most common reported were hemoglobin/hematocrit <7 g/dL or 21% (31.0%), platelet count <50 × 10 9 /L (24.1%), fibrinogen <100 mg/dL (65.3%), aPTT >reference range and >1.5 times reference range (tied, 28.1%), and INR >1.5 (20.7%). Conclusions: Practice variation exists in hemostasis laboratory testing and threshold values for action with TPE. Further studies are needed to determine optimal hemostasis testing strategies with TPE.

KW - coagulation

KW - fibrinogen

KW - international normalized ratio

KW - partial thromboplastin time

KW - plasmapheresis

UR - http://www.scopus.com/inward/record.url?scp=85055720474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055720474&partnerID=8YFLogxK

U2 - 10.1002/jca.21666

DO - 10.1002/jca.21666

M3 - Article

C2 - 30375048

AN - SCOPUS:85055720474

VL - 34

SP - 26

EP - 32

JO - Journal of Clinical Apheresis

JF - Journal of Clinical Apheresis

SN - 0733-2459

IS - 1

ER -